blocking antibody to human ifnar 21385–1 Search Results


human ifnar blocking antibody pbl assay #21385–1  (PBL Assay)
90
PBL Assay human ifnar blocking antibody pbl assay #21385–1
( A – C ) HFFs were treated with human <t>IFNAR</t> <t>blocking</t> antibody or isotype control at 5 μg/mL for 1 h, then were infected with CHIKV-GFP for 24 h at the indicated MOI, followed by CHIKV-mCherry at MOI 1 for 24 h. Blocking antibody treatment was maintained throughout the experiment. Representative flow cytometry plots (A) and quantification of infected cells (C) and are shown. Arrows highlight the difference in GFP infection between isotype control and blocking antibody treated samples. MX1 RNA levels were assessed by RT–qPCR (B). ( D , E ) WT (D) or Irf3 −/− Irf7 −/− MEF cells (E) were infected with CHIKV-GFP at the indicated MOI for 16 h, then with CHIKV-mCherry at MOI 5 (WT) or 3 ( Irf3 −/− Irf7 −/− ) for 8 h, and subsequently analyzed by flow cytometry. Bars indicate mean and SD of biological triplicates, and data are representative of at least two independent experiments. NS, not significant; *** p < 0.001 (one-way analysis of variance followed by Dunnett’s post-test).
Human Ifnar Blocking Antibody Pbl Assay #21385–1, supplied by PBL Assay, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human ifnar blocking antibody pbl assay #21385–1/product/PBL Assay
Average 90 stars, based on 1 article reviews
human ifnar blocking antibody pbl assay #21385–1 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
blocking antibody to human ifnar 21385–1  (PBL Assay)
90
PBL Assay blocking antibody to human ifnar 21385–1
(A) TNF-α and CXCL-1 protein levels after indicated stimulations ± treatment with eIF4E inhibitor 4EGi-1 in B6, Ifnb −/− , and RIP1 Ki Ifnb −/− BMDMs. (B) p-eIF4E and total 4E-BP levels in B6, Ifnb −/− , and RIP1 Ki BMDMs stimulated as indicated ± 5 IU IFNβ priming overnight. (C) TNF-α and CXCL-1 protein levels after indicated stimulations ± treatment with mTORC1 inhibitor Torin 2 in B6, Ifnb −/− , and RIP1 Ki Ifnb −/− BMDMs. (D and E) Cell death as measured by propidium iodide incorporation over 6 h in B6, Ifnb −/− , and RIP1 Ki Ifnb −/− BMDMs stimulated with LZ ± treatment with 4EGi-1 (D) or Torin 2 (E). (F) TNF-α and CXCL-1 protein levels after indicated stimulations ± overnight treatment <t>with</t> <t>IFNAR-blocking</t> antibody (αIFNAR) in Akt1 −/− and wild-type (WT) littermate BMDMs. In all panels, BMDMs were stimulated with LPS, LZ, LZNs, Z, Ns, or LZN as indicated. ELISA and qPCR data are shown as ±SD from three independent experiments compared using two-way ANOVA: n.s. (p > 0.05), *p < 0.05, and ****p < 0.0001. Western blot and kinetic cell death experiments are representative of three or more independent experiments. Kinetic data are presented as the mean ± SD of triplicate wells. See also and .
Blocking Antibody To Human Ifnar 21385–1, supplied by PBL Assay, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/blocking antibody to human ifnar 21385–1/product/PBL Assay
Average 90 stars, based on 1 article reviews
blocking antibody to human ifnar 21385–1 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


( A – C ) HFFs were treated with human IFNAR blocking antibody or isotype control at 5 μg/mL for 1 h, then were infected with CHIKV-GFP for 24 h at the indicated MOI, followed by CHIKV-mCherry at MOI 1 for 24 h. Blocking antibody treatment was maintained throughout the experiment. Representative flow cytometry plots (A) and quantification of infected cells (C) and are shown. Arrows highlight the difference in GFP infection between isotype control and blocking antibody treated samples. MX1 RNA levels were assessed by RT–qPCR (B). ( D , E ) WT (D) or Irf3 −/− Irf7 −/− MEF cells (E) were infected with CHIKV-GFP at the indicated MOI for 16 h, then with CHIKV-mCherry at MOI 5 (WT) or 3 ( Irf3 −/− Irf7 −/− ) for 8 h, and subsequently analyzed by flow cytometry. Bars indicate mean and SD of biological triplicates, and data are representative of at least two independent experiments. NS, not significant; *** p < 0.001 (one-way analysis of variance followed by Dunnett’s post-test).

Journal: PLoS ONE

Article Title: Chikungunya virus superinfection exclusion is mediated by a block in viral replication and does not rely on non-structural protein 2

doi: 10.1371/journal.pone.0241592

Figure Lengend Snippet: ( A – C ) HFFs were treated with human IFNAR blocking antibody or isotype control at 5 μg/mL for 1 h, then were infected with CHIKV-GFP for 24 h at the indicated MOI, followed by CHIKV-mCherry at MOI 1 for 24 h. Blocking antibody treatment was maintained throughout the experiment. Representative flow cytometry plots (A) and quantification of infected cells (C) and are shown. Arrows highlight the difference in GFP infection between isotype control and blocking antibody treated samples. MX1 RNA levels were assessed by RT–qPCR (B). ( D , E ) WT (D) or Irf3 −/− Irf7 −/− MEF cells (E) were infected with CHIKV-GFP at the indicated MOI for 16 h, then with CHIKV-mCherry at MOI 5 (WT) or 3 ( Irf3 −/− Irf7 −/− ) for 8 h, and subsequently analyzed by flow cytometry. Bars indicate mean and SD of biological triplicates, and data are representative of at least two independent experiments. NS, not significant; *** p < 0.001 (one-way analysis of variance followed by Dunnett’s post-test).

Article Snippet: Human IFNAR blocking antibody (PBL Assay Science #21385–1) was used at a concentration of 5 μg/mL, ActD (Sigma-Aldrich #A1410) at 2 μg/μL.

Techniques: Blocking Assay, Control, Infection, Flow Cytometry, Quantitative RT-PCR

(A) TNF-α and CXCL-1 protein levels after indicated stimulations ± treatment with eIF4E inhibitor 4EGi-1 in B6, Ifnb −/− , and RIP1 Ki Ifnb −/− BMDMs. (B) p-eIF4E and total 4E-BP levels in B6, Ifnb −/− , and RIP1 Ki BMDMs stimulated as indicated ± 5 IU IFNβ priming overnight. (C) TNF-α and CXCL-1 protein levels after indicated stimulations ± treatment with mTORC1 inhibitor Torin 2 in B6, Ifnb −/− , and RIP1 Ki Ifnb −/− BMDMs. (D and E) Cell death as measured by propidium iodide incorporation over 6 h in B6, Ifnb −/− , and RIP1 Ki Ifnb −/− BMDMs stimulated with LZ ± treatment with 4EGi-1 (D) or Torin 2 (E). (F) TNF-α and CXCL-1 protein levels after indicated stimulations ± overnight treatment with IFNAR-blocking antibody (αIFNAR) in Akt1 −/− and wild-type (WT) littermate BMDMs. In all panels, BMDMs were stimulated with LPS, LZ, LZNs, Z, Ns, or LZN as indicated. ELISA and qPCR data are shown as ±SD from three independent experiments compared using two-way ANOVA: n.s. (p > 0.05), *p < 0.05, and ****p < 0.0001. Western blot and kinetic cell death experiments are representative of three or more independent experiments. Kinetic data are presented as the mean ± SD of triplicate wells. See also and .

Journal: Cell reports

Article Title: Constitutive Interferon Attenuates RIPK1/3-Mediated Cytokine Translation

doi: 10.1016/j.celrep.2019.12.073

Figure Lengend Snippet: (A) TNF-α and CXCL-1 protein levels after indicated stimulations ± treatment with eIF4E inhibitor 4EGi-1 in B6, Ifnb −/− , and RIP1 Ki Ifnb −/− BMDMs. (B) p-eIF4E and total 4E-BP levels in B6, Ifnb −/− , and RIP1 Ki BMDMs stimulated as indicated ± 5 IU IFNβ priming overnight. (C) TNF-α and CXCL-1 protein levels after indicated stimulations ± treatment with mTORC1 inhibitor Torin 2 in B6, Ifnb −/− , and RIP1 Ki Ifnb −/− BMDMs. (D and E) Cell death as measured by propidium iodide incorporation over 6 h in B6, Ifnb −/− , and RIP1 Ki Ifnb −/− BMDMs stimulated with LZ ± treatment with 4EGi-1 (D) or Torin 2 (E). (F) TNF-α and CXCL-1 protein levels after indicated stimulations ± overnight treatment with IFNAR-blocking antibody (αIFNAR) in Akt1 −/− and wild-type (WT) littermate BMDMs. In all panels, BMDMs were stimulated with LPS, LZ, LZNs, Z, Ns, or LZN as indicated. ELISA and qPCR data are shown as ±SD from three independent experiments compared using two-way ANOVA: n.s. (p > 0.05), *p < 0.05, and ****p < 0.0001. Western blot and kinetic cell death experiments are representative of three or more independent experiments. Kinetic data are presented as the mean ± SD of triplicate wells. See also and .

Article Snippet: Blocking antibody to Human IFNAR (21385–1) was purchased from PBL Assay Science and used at 20ug/ml.

Techniques: Blocking Assay, Enzyme-linked Immunosorbent Assay, Western Blot

(A) Cell death as measured by propidium iodide incorporation over 8 h in human PBMC-derived macrophages stimulated as indicated ± overnight treatment with IFNAR-blocking antibody. (B and C) CXCL-1 protein (B) and mRNA (C) levels in human PBMC-derived macrophages stimulated as indicated ± overnight treatment with IFNAR-blocking antibody (D and E) CXCL-1 protein (D) and mRNA (E) levels in human PBMC-derived macrophages stimulated as indicated ± overnight treatment with IFNAR-blocking antibody and/or treatment with 4EGi-1 or Torin 2. In all panels, human PBMC-derived macrophages were stimulated with LPS, LZ, or LZNs as indicated. ELISA and qPCR data are shown as ±SD from three independent experiments compared using two-way ANOVA: n.s. (p > 0.05), **p < 0.01, ***p < 0.001, and ****p < 0.0001. Kinetic cell death experiments are representative of three or more independent experiments and presented as the mean ± SD of triplicate wells.

Journal: Cell reports

Article Title: Constitutive Interferon Attenuates RIPK1/3-Mediated Cytokine Translation

doi: 10.1016/j.celrep.2019.12.073

Figure Lengend Snippet: (A) Cell death as measured by propidium iodide incorporation over 8 h in human PBMC-derived macrophages stimulated as indicated ± overnight treatment with IFNAR-blocking antibody. (B and C) CXCL-1 protein (B) and mRNA (C) levels in human PBMC-derived macrophages stimulated as indicated ± overnight treatment with IFNAR-blocking antibody (D and E) CXCL-1 protein (D) and mRNA (E) levels in human PBMC-derived macrophages stimulated as indicated ± overnight treatment with IFNAR-blocking antibody and/or treatment with 4EGi-1 or Torin 2. In all panels, human PBMC-derived macrophages were stimulated with LPS, LZ, or LZNs as indicated. ELISA and qPCR data are shown as ±SD from three independent experiments compared using two-way ANOVA: n.s. (p > 0.05), **p < 0.01, ***p < 0.001, and ****p < 0.0001. Kinetic cell death experiments are representative of three or more independent experiments and presented as the mean ± SD of triplicate wells.

Article Snippet: Blocking antibody to Human IFNAR (21385–1) was purchased from PBL Assay Science and used at 20ug/ml.

Techniques: Derivative Assay, Blocking Assay, Enzyme-linked Immunosorbent Assay

Journal: Cell reports

Article Title: Constitutive Interferon Attenuates RIPK1/3-Mediated Cytokine Translation

doi: 10.1016/j.celrep.2019.12.073

Figure Lengend Snippet:

Article Snippet: Blocking antibody to Human IFNAR (21385–1) was purchased from PBL Assay Science and used at 20ug/ml.

Techniques: Purification, Recombinant, Enzyme-linked Immunosorbent Assay, RNA Sequencing, Derivative Assay